

The following changes will be made to the Preferred Drug List (PDL), effective July 1, 2020, by approval of DOM's Executive Director.

For a comprehensive PDL, refer to http://www.medicaid.ms.gov/providers/pharmacy/preferred-druglist/.NEW

NEW PREFERRED DRUGS

THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
ANTICONVULSANTS	VALTOCO (diazepam)
ANTIMIGRAINE AGENTS, CALCITONIN GENE RELATED PEPTIDE INHIBITOR	NURTEC ODT (rimegepant)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ACNE AGENTS, COMBINATION DRUGS	EPIDUO (adapalene/benzoyl peroxide)
ANTINEOPLASTIC, SELECT SYSTEMIC ENZYME INHIBITORS	GLEEVAC (imatinib mesylate)
IMMUNOSUPPRESIVE, ORAL	MYFORTIC (mycophenolic acid)
IRON CHELATING AGENTS	EXJADE (deferasirox)
MISCELLANEOUS, BRAND/GENERIC	CATAPRESS TTS (clonidine)
STEROIDS, TOPICAL, VERY HIGH POTENCY	CLOBEX (clobetasol)
ULCERATIVE COLITIS & CROHNS	APRISO (mesalamine)